The Global Health Body Sounds Concern Over Severe Lack of Weight-Loss Medications

Fewer than one in 10 people that would benefit from obesity jabs like Wegovy can access them, caution the WHO as it publishes its first recommendations on the therapies.

Considering over a billion people worldwide now living with obesity, it is calling for increased and just access to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"The new guidelines acknowledges that excess weight is a chronic disease that can be managed with comprehensive and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to universal availability to the injections that can aid individuals in losing substantial body mass, says the body.

Weight-Loss Drug Supply Crisis

Even in the present most favorable case, the production of GLP-1 therapies might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.

The recommendation calls on governments and firms to expand access, via approaches including voluntary licensing.

The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.

The Way Weight-Loss Jabs Work

These medications imitate a biological compound to slow digestion, curb appetite and enhance feelings of fullness so individuals reduce food intake.

Patients typically see weight reduction within a few weeks of commencing the weekly injections.

Studies indicates people may see weight return within a year of stopping the treatment, as their typical appetite come back.

Being above a healthy weight elevates your risk for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.

Obesity affects people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the WHO.